Human Papillomavirus virus like particles (VLPs) have been constructed so that they contain a modified L2 protein. The L2 protein has been minimized and is fused to a second protein or peptide. The fused protein is incorporated into the VLP and the VLP can deliver the protein to a cell. The modified VLPs can be used to increase the breadth of immune response in vaccine preparations or to deliver other proteins of interest.

 
Web www.patentalert.com

< Neurturin antibody

< Isoflavone derivatives

> Liposome composition for delivery of nucleic acid

> 3terminal sequence of hepatitis C virus genome and diagnostic and therapeutic uses thereof

~ 00234